CommercialCoverageMedium impact
08.00.91f, Alpha-1 Antitrypsin Therapy (e.g., Prolastin-C®, Aralast NP®, Glassia®, Zemaira®)
Independence Blue Cross·Pulmonology, Internal Medicine·Pharmacy
Effective date
Apr 29, 2026
We identified it
Jun 19, 2026
Summary
Alpha-1 Antitrypsin Therapy policy (covering Prolastin-C®, Aralast NP®, Glassia®, Zemaira®) has been reissued for commercial plans. This is a fresh policy update that may contain updated coverage criteria or administrative requirements for these specialty pharmacy treatments.
Action Required
Before April 29, 2026: Billing and clinical teams should review the updated Alpha-1 Antitrypsin Therapy policy at the provided URL to identify any changes in coverage criteria, prior authorization requirements, or documentation standards for Prolastin-C®, Aralast NP®, Glassia®, and Zemaira®. Update any internal protocols accordingly.